特宝生物：产品益佩生新增适应症获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Teabo Bio (SH 688278) has received approval from the National Medical Products Administration for a new indication of its product Yipei Sheng for "Adult Growth Hormone Deficiency (AGHD)" [2] - Teabo Bio's revenue composition for the year 2024 is projected to be 99.73% from biopharmaceuticals and 0.27% from other businesses [2]